Trial Profile
A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Arhalofenate (Primary) ; Allopurinol; Colchicine
- Indications Gout
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 28 Mar 2016 Results were published in a CymaBay Therapeutics media release.
- 18 Mar 2016 Results published in the Arthritis and Rheumatology.
- 05 Nov 2015 Results published in a CymaBay Therapeutics media release.